Barclays PLC Grows Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Barclays PLC raised its position in SI-BONE, Inc. (NASDAQ:SIBN) by 190.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,623 shares of the company’s stock after buying an additional 63,402 shares during the period. Barclays PLC owned approximately 0.23% of SI-BONE worth $1,350,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. FMR LLC lifted its stake in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in SI-BONE during the 2nd quarter worth approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in SI-BONE by 24.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock worth $138,000 after purchasing an additional 2,108 shares during the last quarter. Arizona State Retirement System raised its position in shares of SI-BONE by 9.0% in the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock valued at $141,000 after purchasing an additional 903 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of SI-BONE during the 3rd quarter valued at approximately $144,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,937 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.60, for a total value of $49,606.20. Following the sale, the insider now owns 228,554 shares of the company’s stock, valued at approximately $2,879,780.40. This trade represents a 1.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Anshul Maheshwari sold 2,439 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.68, for a total value of $30,926.52. Following the transaction, the chief financial officer now owns 194,623 shares of the company’s stock, valued at $2,467,819.64. This represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,679 shares of company stock valued at $276,439. Company insiders own 3.90% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the topic of several recent analyst reports. Truist Financial upped their price target on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research note on Wednesday, November 20th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $23.00.

SI-BONE Stock Performance

SI-BONE stock opened at $13.72 on Friday. The company has a market cap of $575.39 million, a PE ratio of -14.91 and a beta of 1.20. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $21.64. The company has a fifty day moving average price of $13.46 and a two-hundred day moving average price of $14.08. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.